Clinical trials: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood.
- Conditions
- Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy
- Trial name
- NCT07855302
- Testing
- SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Seoul National University Hospital
Refractory Systemic Lupus Erythematosus
CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
The goal of this Phase I clinical trial is to evaluate the safety and tolerability of autologous CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy in adults with refractory systemic lupus erythematosus who have…
- Trial name
- NCT07432334
- Testing
- Autologous CD19-Targeted CAR-T Cells
- Where
- Vietnam
- Volunteers
- 8 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Autologous Stem Cell Transplantation: International Lupus Trial
The purpose of this study is to evaluate remission induction therapy for refractory Lupus Erythematosus with autologous hematopoietic stem cell transplantation (AHSCT) versus Rituximab (anti CD20) followed by maintenance therapy…
- Trial name
- ASTIL (NCT05063513)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Rituximab
- Where
- France
- Sponsor
- European Society for Blood and Marrow Transplantation
Refractory Systemic Lupus Erythematosus
Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)
This study will explore a new approach to treat patients with a medical condition known as systemic lupus erythematosus (SLE) who have been resistant to previous treatments using a new population of cells with capability to…
- Trial name
- NCT00698191
- Testing
- Allogeneic MSC (AlloMSC)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Medical University